The Ministry of Food and Drug Safety noted on the 24th that it will approve the use of the systemic Myasthenia Gravis treatment, Listigoju (Rozanolixizumab). Myasthenia Gravis is a rare disease characterized by the gradual weakening of muscle strength.
Myasthenia Gravis occurs when there are excessively high levels of antibodies in the body. An abundance of antibodies interferes with the signals that transmit muscle movement to the neuromuscular junction. This treatment involves lowering the concentration of antibodies by participating in the process of continuous antibody production in the body. The principle is to appropriately regulate antibodies to ensure that signals for muscle movement are effectively transmitted.
A Ministry of Food and Drug Safety official said, "The range of options for patients will be broadened when treating systemic Myasthenia Gravis."